FI932445A0 - Farmaceutiska foereningar - Google Patents

Farmaceutiska foereningar

Info

Publication number
FI932445A0
FI932445A0 FI932445A FI932445A FI932445A0 FI 932445 A0 FI932445 A0 FI 932445A0 FI 932445 A FI932445 A FI 932445A FI 932445 A FI932445 A FI 932445A FI 932445 A0 FI932445 A0 FI 932445A0
Authority
FI
Finland
Prior art keywords
alkyl
optionally substituted
pharmaceutical production
cycloalkyl
alkyl groups
Prior art date
Application number
FI932445A
Other languages
English (en)
Other versions
FI932445A (fi
FI101538B1 (fi
FI101538B (fi
Inventor
John Fairhurst
Terrence Michael Hotten
David Edward Tupper
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211379A external-priority patent/GB9211379D0/en
Priority claimed from GB939309025A external-priority patent/GB9309025D0/en
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of FI932445A0 publication Critical patent/FI932445A0/fi
Publication of FI932445A publication Critical patent/FI932445A/fi
Application granted granted Critical
Publication of FI101538B1 publication Critical patent/FI101538B1/fi
Publication of FI101538B publication Critical patent/FI101538B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI932445A 1992-05-29 1993-05-28 Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-mety yli-1-piperatsinyyli)-10H-tieno£2,3-b|£1,5|bentsodiatsepiinijohdannais ten valmistamiseksi FI101538B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211379A GB9211379D0 (en) 1992-05-29 1992-05-29 Pharmaceutical compounds
GB939309025A GB9309025D0 (en) 1993-04-30 1993-04-30 Pharmaceutical compounds

Publications (4)

Publication Number Publication Date
FI932445A0 true FI932445A0 (fi) 1993-05-28
FI932445A FI932445A (fi) 1993-11-30
FI101538B1 FI101538B1 (fi) 1998-07-15
FI101538B FI101538B (fi) 1998-07-15

Family

ID=26300951

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932445A FI101538B (fi) 1992-05-29 1993-05-28 Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-mety yli-1-piperatsinyyli)-10H-tieno£2,3-b|£1,5|bentsodiatsepiinijohdannais ten valmistamiseksi

Country Status (21)

Country Link
EP (1) EP0582368B1 (fi)
JP (1) JP3219541B2 (fi)
CN (1) CN1043994C (fi)
AT (1) ATE198891T1 (fi)
AU (1) AU668159B2 (fi)
CA (1) CA2097016A1 (fi)
CZ (1) CZ282783B6 (fi)
DE (1) DE69329887T2 (fi)
DK (1) DK0582368T3 (fi)
ES (1) ES2153373T3 (fi)
FI (1) FI101538B (fi)
GR (1) GR3035587T3 (fi)
HU (1) HU218278B (fi)
IL (1) IL105827A (fi)
MX (1) MX9303124A (fi)
MY (1) MY109943A (fi)
NO (1) NO305125B1 (fi)
NZ (1) NZ247703A (fi)
PT (1) PT582368E (fi)
RU (1) RU2125574C1 (fi)
TW (1) TW268005B (fi)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
PL329221A1 (en) * 1996-03-25 1999-03-15 Lilly Co Eli Method of relieving hemicrania pains
CA2250187A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Composition comprising olanzapine and a drug useful in the treatment of pain for use in the treatment of pain
CA2248873A1 (en) * 1996-03-25 1997-10-02 Daniel Edward Womer Method for treating pain
ID21924A (id) * 1996-09-23 1999-08-12 Lilly Co Eli Olanzapin dihidrat d
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
TR199900651T2 (xx) * 1996-09-24 1999-07-21 Eli Lilly And Company Kaplanm�� par�ac�k form�lasyonu.
WO2014031603A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to paliperidone haptens and use thereof
CN104736561B (zh) 2012-08-21 2018-06-12 詹森药业有限公司 帕潘立酮的抗体及其用途
EP3492473A1 (en) * 2012-08-21 2019-06-05 Janssen Pharmaceutica NV Haptens of olanzipine
CA2882594C (en) 2012-08-21 2019-07-16 Ortho-Clinical Diagnostics, Inc. Antibodies to risperidone and use thereof
PL3385284T3 (pl) 2012-08-21 2020-09-21 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PT2888257T (pt) 2012-08-21 2017-11-14 Janssen Pharmaceutica Nv Haptenos de quetiapina para utilização em ensaios imunológicos
TR201809424T4 (tr) 2012-08-21 2018-07-23 Janssen Pharmaceutica Nv Risperidon ve paliperidon haptenleri.
CA2882492C (en) 2012-08-21 2019-05-28 Ortho-Clinical Diagnostics, Inc. Antibodies to aripiprazole haptens and use thereof
AU2013305884B2 (en) 2012-08-21 2017-10-05 Saladax Biomedical Inc. Antibodies to risperidone haptens and use thereof
ES2971506T3 (es) 2012-08-21 2024-06-05 Janssen Pharmaceutica Nv Haptenos de paliperidona
EP2888590B1 (en) 2012-08-21 2020-07-08 Janssen Pharmaceutica NV Antibodies to olanzapine and use thereof
CA2882615C (en) 2012-08-21 2019-07-09 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine and use thereof
PL2888234T3 (pl) 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
JP6389177B2 (ja) 2012-08-21 2018-09-12 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンハプテンに対する抗体及びその使用
EP3390455A1 (en) 2015-12-17 2018-10-24 Janssen Pharmaceutica NV Antibodies to quetiapine and use thereof
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
SE7610219L (sv) * 1975-09-24 1977-03-25 Sandoz Ag Nya dibenso /b,e//1,4/ diazepiner
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
JP3219541B2 (ja) 2001-10-15
CN1043994C (zh) 1999-07-07
NZ247703A (en) 1995-07-26
IL105827A0 (en) 1993-09-22
CZ102493A3 (en) 1993-12-15
NO931917L (no) 1993-11-30
TW268005B (fi) 1996-01-11
DE69329887T2 (de) 2001-05-23
CN1085903A (zh) 1994-04-27
DK0582368T3 (da) 2001-02-05
MX9303124A (es) 1993-11-01
CA2097016A1 (en) 1993-11-30
NO305125B1 (no) 1999-04-06
IL105827A (en) 1997-02-18
RU2125574C1 (ru) 1999-01-27
EP0582368A1 (en) 1994-02-09
CZ282783B6 (cs) 1997-10-15
HUT66180A (en) 1994-09-28
JPH0687862A (ja) 1994-03-29
HU218278B (en) 2000-07-28
GR3035587T3 (en) 2001-06-29
FI932445A (fi) 1993-11-30
HU9301579D0 (en) 1993-09-28
EP0582368B1 (en) 2001-01-24
DE69329887D1 (de) 2001-03-01
AU3980793A (en) 1993-12-02
FI101538B1 (fi) 1998-07-15
PT582368E (pt) 2001-05-31
AU668159B2 (en) 1996-04-26
ES2153373T3 (es) 2001-03-01
ATE198891T1 (de) 2001-02-15
NO931917D0 (no) 1993-05-26
FI101538B (fi) 1998-07-15
MY109943A (en) 1997-10-31

Similar Documents

Publication Publication Date Title
FI932445A0 (fi) Farmaceutiska foereningar
KR930703355A (ko) 항생물질 ge2270 인자의 아미드
PH25859A (en) Composition for treatment of ischemic disorder
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.
SE9100920D0 (sv) New active compounds
ATE117989T1 (de) Prostaglandinanaloge enthaltende lipidemulsion.
NO894349D0 (no) Tienopyridin-type mevalonolaktoner.
FI891279A (fi) Antivirala tetrahydroimidazol /1,4/ benzodiazepin-2-oner.
EP0103320A3 (en) Acetylsalicylic acid thioesters, a process for their preparation and pharmaceutical compositions containing them
FI103885B1 (fi) Menetelmä terapeuttisesti aktiivisten 1-bentsyyli-4-fenyylipiperatsiinijohdannaisten valmistamiseksi ja välituotteina käyttökelpoisia yhdisteitä
TW275629B (fi)
GB8709546D0 (en) Pharmaceutical use of organic compounds
PT83110A (fr) Procede de preparation de l'acide 2-(5-chloro-4-nitro-2-methoxybenzamido)-acetohydroxamique
GB8823042D0 (en) Organic compounds & their use as pharmaceuticals